Skye Bioscience Updates Phase 1 Timeline
July 20, 2022
Ryan Allway July 20th, 2022 News, Top News San Diego, California, July 20, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) of its Phase... Read more
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
January 4, 2022
Ryan Allway January 4th, 2022 Psychedelics – Last subject completed study in late 2021 with topline results expected in early 2022 – – Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal – NEW YORK, Jan. 4, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED),... Read more
